Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

Molecular Ablation of Tumor Blood Vessels Inhibits Therapeutic Effects of Radiation and Bevacizumab.

Yadav VN, Altshuler D, Kadiyala P, Zamler D, Comba A, Appelman H, Dunn P, Koschmann C, Castro MG, Löwenstein PR.

Neuro Oncol. 2018 Apr 12. doi: 10.1093/neuonc/noy055. [Epub ahead of print]

PMID:
29660022
2.

Native Chromatin Immunoprecipitation Using Murine Brain Tumor Neurospheres.

Mendez FM, Núñez FJ, Zorrilla-Veloz RI, Lowenstein PR, Castro MG.

J Vis Exp. 2018 Jan 29;(131). doi: 10.3791/57016.

3.

Current state and future prospects of immunotherapy for glioma.

Kamran N, Alghamri MS, Nunez FJ, Shah D, Asad AS, Candolfi M, Altshuler D, Lowenstein PR, Castro MG.

Immunotherapy. 2018 Feb 1;10(4):317-339. doi: 10.2217/imt-2017-0122.

PMID:
29421984
4.

Melanoma induced immunosuppression is mediated by hematopoietic dysregulation.

Kamran N, Li Y, Sierra M, Alghamri MS, Kadiyala P, Appelman HD, Edwards M, Lowenstein PR, Castro MG.

Oncoimmunology. 2017 Dec 14;7(3):e1408750. doi: 10.1080/2162402X.2017.1408750. eCollection 2018. Erratum in: Oncoimmunology. 2018 Feb 1;7(4):e1431073.

PMID:
29399415
5.

Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

Lowenstein PR, Castro MG.

Clin Immunol. 2018 Apr;189:43-51. doi: 10.1016/j.clim.2017.07.006. Epub 2017 Jul 15.

PMID:
28720549
6.

Single vs. combination immunotherapeutic strategies for glioma.

Chandran M, Candolfi M, Shah D, Mineharu Y, Yadav VN, Koschmann C, Asad AS, Lowenstein PR, Castro MG.

Expert Opin Biol Ther. 2017 May;17(5):543-554. doi: 10.1080/14712598.2017.1305353. Epub 2017 Mar 20. Review.

7.

Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.

Kamran N, Kadiyala P, Saxena M, Candolfi M, Li Y, Moreno-Ayala MA, Raja N, Shah D, Lowenstein PR, Castro MG.

Mol Ther. 2017 Jan 4;25(1):232-248. doi: 10.1016/j.ymthe.2016.10.003. Epub 2017 Jan 4.

8.

Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer.

Koschmann C, Nunez FJ, Mendez F, Brosnan-Cashman JA, Meeker AK, Lowenstein PR, Castro MG.

Cancer Res. 2017 Jan 15;77(2):227-233. doi: 10.1158/0008-5472.CAN-16-2301. Epub 2017 Jan 6. Review.

9.

Matrix Metalloproteinase Activity in Infections by an Encephalitic Virus, Mouse Adenovirus Type 1.

Ashley SL, Pretto CD, Stier MT, Kadiyala P, Castro-Jorge L, Hsu TH, Doherty R, Carnahan KE, Castro MG, Lowenstein PR, Spindler KR.

J Virol. 2017 Feb 28;91(6). pii: e01412-16. doi: 10.1128/JVI.01412-16. Print 2017 Mar 15.

10.

CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study.

Yadav VN, Zamler D, Baker GJ, Kadiyala P, Erdreich-Epstein A, DeCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR.

Oncotarget. 2016 Dec 13;7(50):83701-83719. doi: 10.18632/oncotarget.13295.

11.

Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.

Kamran N, Chandran M, Lowenstein PR, Castro MG.

Clin Immunol. 2018 Apr;189:34-42. doi: 10.1016/j.clim.2016.10.008. Epub 2016 Oct 21.

12.

Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.

Koschmann C, Zamler D, MacKay A, Robinson D, Wu YM, Doherty R, Marini B, Tran D, Garton H, Muraszko K, Robertson P, Leonard M, Zhao L, Bixby D, Peterson L, Camelo-Piragua S, Jones C, Mody R, Lowenstein PR, Castro MG.

Oncotarget. 2016 Oct 4;7(40):65696-65706. doi: 10.18632/oncotarget.11602.

14.

Survival and Proliferation of Neural Progenitor-Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism.

Calinescu AA, Yadav VN, Carballo E, Kadiyala P, Tran D, Zamler DB, Doherty R, Srikanth M, Lowenstein PR, Castro MG.

Clin Cancer Res. 2017 Mar 1;23(5):1250-1262. doi: 10.1158/1078-0432.CCR-15-2888. Epub 2016 Aug 19.

15.

Multiple Expressed Endogenous Glioma Epitopes as Novel Vaccines for Gliomas.

Lowenstein PR, Castro MG.

Clin Cancer Res. 2016 Oct 1;22(19):4760-4762. Epub 2016 Aug 12.

16.

Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells.

Baker GJ, Chockley P, Zamler D, Castro MG, Lowenstein PR.

Oncoimmunology. 2016 Mar 16;5(6):e1163461. doi: 10.1080/2162402X.2016.1163461. eCollection 2016 Jun.

17.

Recent advances and future of immunotherapy for glioblastoma.

Kamran N, Calinescu A, Candolfi M, Chandran M, Mineharu Y, Asad AS, Koschmann C, Nunez FJ, Lowenstein PR, Castro MG.

Expert Opin Biol Ther. 2016 Oct;16(10):1245-64. doi: 10.1080/14712598.2016.1212012. Epub 2016 Jul 27. Review.

18.

ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability.

Koschmann C, Lowenstein PR, Castro MG.

Mol Cell Oncol. 2016 Apr 27;3(3):e1167158. doi: 10.1080/23723556.2016.1167158. eCollection 2016 May.

19.

The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.

Lowenstein PR, Castro MG.

Adv Pharmacol. 2016;76:147-73. doi: 10.1016/bs.apha.2016.03.002. Epub 2016 Apr 23. Review.

20.

Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model.

VanderVeen N, Raja N, Yi E, Appelman H, Ng P, Palmer D, Zamler D, Dzaman M, Lowenstein PR, Castro MG.

Hum Gene Ther Methods. 2016 Jun;27(3):98-111. doi: 10.1089/hgtb.2015.168. Epub 2016 Apr 28.

21.

ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.

Koschmann C, Calinescu AA, Nunez FJ, Mackay A, Fazal-Salom J, Thomas D, Mendez F, Kamran N, Dzaman M, Mulpuri L, Krasinkiewicz J, Doherty R, Lemons R, Brosnan-Cashman JA, Li Y, Roh S, Zhao L, Appelman H, Ferguson D, Gorbunova V, Meeker A, Jones C, Lowenstein PR, Castro MG.

Sci Transl Med. 2016 Mar 2;8(328):328ra28. doi: 10.1126/scitranslmed.aac8228.

22.

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells.

Baker GJ, Castro MG, Lowenstein PR.

J Vis Exp. 2015 Nov 28;(105). doi: 10.3791/53676.

23.

Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms.

Kamran N, Candolfi M, Baker GJ, Ayala MM, Dzaman M, Lowenstein PR, Castro MG.

Methods Mol Biol. 2016;1382:467-82. doi: 10.1007/978-1-4939-3271-9_31.

24.

Overview of current immunotherapeutic strategies for glioma.

Calinescu AA, Kamran N, Baker G, Mineharu Y, Lowenstein PR, Castro MG.

Immunotherapy. 2015;7(10):1073-104. doi: 10.2217/imt.15.75. Review.

25.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

26.

Cracking the glioma-NK inhibitory code: toward successful innate immunotherapy.

Lowenstein PR, Baker GJ, Castro MG.

Oncoimmunology. 2014 Dec 21;3(11):e965573. eCollection 2014 Nov.

27.

Transposon mediated integration of plasmid DNA into the subventricular zone of neonatal mice to generate novel models of glioblastoma.

Calinescu AA, Núñez FJ, Koschmann C, Kolb BL, Lowenstein PR, Castro MG.

J Vis Exp. 2015 Feb 22;(96). doi: 10.3791/52443.

28.

Glioma trials and viral tribulations: can anything be concluded from non-controlled trials?

Lowenstein PR, Castro MG.

J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):125. doi: 10.1136/jnnp-2014-308406. Epub 2014 Oct 3. No abstract available.

29.

Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.

Mineharu Y, Kamran N, Lowenstein PR, Castro MG.

Mol Cancer Ther. 2014 Dec;13(12):3024-36. doi: 10.1158/1535-7163.MCT-14-0400. Epub 2014 Sep 25.

30.

Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.

Baker GJ, Yadav VN, Motsch S, Koschmann C, Calinescu AA, Mineharu Y, Camelo-Piragua SI, Orringer D, Bannykh S, Nichols WS, deCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR.

Neoplasia. 2014 Jul;16(7):543-61. doi: 10.1016/j.neo.2014.06.003.

31.

Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.

VanderVeen N, Paran C, Appelhans A, Krasinkiewicz J, Lemons R, Appelman H, Doherty R, Palmer D, Ng P, Lowenstein PR, Castro MG.

Mol Ther Methods Clin Dev. 2014 Feb 5;1. pii: 10.

32.

Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity.

Baker GJ, Chockley P, Yadav VN, Doherty R, Ritt M, Sivaramakrishnan S, Castro MG, Lowenstein PR.

Cancer Res. 2014 Sep 15;74(18):5079-90. doi: 10.1158/0008-5472.CAN-14-1203. Epub 2014 Jul 18.

33.

Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier!

Castro MG, Baker GJ, Lowenstein PR.

Clin Cancer Res. 2014 Oct 15;20(20):5147-9. doi: 10.1158/1078-0432.CCR-14-0820. Epub 2014 May 30.

34.

The value of EGFRvIII as the target for glioma vaccines.

Lowenstein PR, Castro MG.

Am Soc Clin Oncol Educ Book. 2014:42-50. doi: 10.14694/EdBook_AM.2014.34.42. Review.

35.

Assessing the role of STAT3 in DC differentiation and autologous DC immunotherapy in mouse models of GBM.

Assi H, Espinosa J, Suprise S, Sofroniew M, Doherty R, Zamler D, Lowenstein PR, Castro MG.

PLoS One. 2014 May 7;9(5):e96318. doi: 10.1371/journal.pone.0096318. eCollection 2014.

36.

Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Castro MG, Candolfi M, Wilson TJ, Calinescu A, Paran C, Kamran N, Koschmann C, Moreno-Ayala MA, Assi H, Lowenstein PR.

Expert Opin Biol Ther. 2014 Sep;14(9):1241-57. doi: 10.1517/14712598.2014.915307. Epub 2014 Apr 29. Review.

37.

Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H.

Lynes J, Wibowo M, Koschmann C, Baker GJ, Saxena V, Muhammad AK, Bondale N, Klein J, Assi H, Lieberman AP, Castro MG, Lowenstein PR.

Neurotherapeutics. 2014 Jul;11(3):623-35. doi: 10.1007/s13311-014-0269-y.

38.

Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy.

Assi HH, Paran C, VanderVeen N, Savakus J, Doherty R, Petruzzella E, Hoeschele JD, Appelman H, Raptis L, Mikkelsen T, Lowenstein PR, Castro MG.

J Pharmacol Exp Ther. 2014 Jun;349(3):458-69. doi: 10.1124/jpet.114.214619. Epub 2014 Apr 2.

39.

Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.

Candolfi M, Yagiz K, Wibowo M, Ahlzadeh GE, Puntel M, Ghiasi H, Kamran N, Paran C, Lowenstein PR, Castro MG.

Clin Cancer Res. 2014 Mar 15;20(6):1555-1565. doi: 10.1158/1078-0432.CCR-13-2140. Epub 2014 Feb 5.

40.

There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease.

Lowenstein PR, Yadav VN, Chockley P, Castro M.

Mol Ther. 2014 Feb;22(2):246-247. doi: 10.1038/mt.2013.297. No abstract available.

41.

Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials.

Mineharu Y, Castro MG, Lowenstein PR, Sakai N, Miyamoto S.

Neurol Med Chir (Tokyo). 2013;53(11):741-54. Epub 2013 Oct 21. Review.

42.

Neuro-oncology: The long and winding road--gene therapy for glioma.

Castro MG, Lowenstein PR.

Nat Rev Neurol. 2013 Nov;9(11):609-10. doi: 10.1038/nrneurol.2013.198. Epub 2013 Sep 24. No abstract available.

43.

Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma.

VanderVeen N, Paran C, Krasinkiewicz J, Zhao L, Palmer D, Hervey-Jumper S, Ng P, Lowenstein PR, Castro MG.

Hum Gene Ther Clin Dev. 2013 Sep;24(3):116-26. doi: 10.1089/humc.2013.139.

44.

Progress in gene therapy for neurological disorders.

Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, Gray SJ, Lowenstein PR, Vandenberghe LH, Wilson TJ, Wolfe JH, Glorioso JC.

Nat Rev Neurol. 2013 May;9(5):277-91. doi: 10.1038/nrneurol.2013.56. Epub 2013 Apr 23. Review. Erratum in: Nat Rev Neurol. 2013 Jun;9(6):298.

45.

Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma.

Puntel M, A K M GM, Farrokhi C, Vanderveen N, Paran C, Appelhans A, Kroeger KM, Salem A, Lacayo L, Pechnick RN, Kelson KR, Kaur S, Kennedy S, Palmer D, Ng P, Liu C, Krasinkiewicz J, Lowenstein PR, Castro MG.

Toxicol Appl Pharmacol. 2013 May 1;268(3):318-30. doi: 10.1016/j.taap.2013.02.001. Epub 2013 Feb 9.

46.

Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.

Mineharu Y, Muhammad AK, Yagiz K, Candolfi M, Kroeger KM, Xiong W, Puntel M, Liu C, Levy E, Lugo C, Kocharian A, Allison JP, Curran MA, Lowenstein PR, Castro MG.

Neurotherapeutics. 2012 Oct;9(4):827-43. doi: 10.1007/s13311-012-0144-7.

47.

Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.

Candolfi M, King GD, Yagiz K, Curtin JF, Mineharu Y, Muhammad AK, Foulad D, Kroeger KM, Barnett N, Josien R, Lowenstein PR, Castro MG.

Neoplasia. 2012 Aug;14(8):757-70.

48.

Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial.

Muhammad AK, Xiong W, Puntel M, Farrokhi C, Kroeger KM, Salem A, Lacayo L, Pechnick RN, Kelson KR, Palmer D, Ng P, Liu C, Lowenstein PR, Castro MG.

Hum Gene Ther Methods. 2012 Aug;23(4):271-84. doi: 10.1089/hgtb.2012.060. Epub 2012 Sep 5.

49.

Gene therapy for brain tumors: basic developments and clinical implementation.

Assi H, Candolfi M, Baker G, Mineharu Y, Lowenstein PR, Castro MG.

Neurosci Lett. 2012 Oct 11;527(2):71-7. doi: 10.1016/j.neulet.2012.08.003. Epub 2012 Aug 10. Review.

50.

Cytotoxic immunological synapses do not restrict the action of interferon-γ to antigenic target cells.

Sanderson NS, Puntel M, Kroeger KM, Bondale NS, Swerdlow M, Iranmanesh N, Yagita H, Ibrahim A, Castro MG, Lowenstein PR.

Proc Natl Acad Sci U S A. 2012 May 15;109(20):7835-40. doi: 10.1073/pnas.1116058109. Epub 2012 Apr 30.

Supplemental Content

Loading ...
Support Center